On 26 May 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) issued a statement reviewing initial reports of mild myocarditis following COVID-19 mRNA vaccines. Myocarditis is an inflammation of the heart muscle and pericarditis is an inflammation of the lining that surrounds the heart. While they can lead to serious illness, they are often mild and respond well to conservative treatment. More data have become available since the GACVS statement of 26 May 2021, with more countries reporting myocarditis and pericarditis in individuals who received COVID-19 mRNA vaccines. The reported cases have typically occurred within days of vaccination, more commonly among younger males often following the second dose the of COVID-19 mRNA vaccines. A strong signal of myocarditis/pericarditis has been reported recently with mRNA COVID-19 vaccines in the United States (US). However, the US Advisory Committee on Immunization Practices (ACIP) has concluded that the benefits of mRNA COVID-19 vaccines continue to outweigh the risks of myocarditis and pericarditis even among young people. According to the data in the US Vaccine Adverse Events Reporting System (VAERS), approximately 40.6 cases of myocarditis per million second doses among males and 4.2 cases per million among females have been reported as of 11 June 2021� in persons 12-29 years of age who received the mRNA COVID-19 vaccines. For persons over 30 years of age, the reporting rates were 2.4 and 1.0 per million second doses, respectively, for males and females.The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) at its recent meeting on 5-8 July 2021 reviewed the latest data from Europe and has confirmed that there is a plausible causal relationship between myocarditis and the mRNA vaccines.The GACVS COVID-19 subcommittee has reviewed all available information to date, and notes the following: The benefits of mRNA COVID-19 vaccines outweigh the risks in reducing hospitalizations and deaths due to COVID-19 infections.Very rare cases of myocarditis and pericarditis have been observed following vaccination with the mRNA COVID-19 vaccines. These cases occurred more often in younger men and after the second dose of the vaccine, typically within few days after vaccination. Current evidence suggests a likely causal association between myocarditis and the mRNA vaccinesAvailable data suggest that the immediate course of myocarditis and pericarditis following vaccination is generally mild and responds to conservative treatment (e.g. rest, treatment with nonsteroidal anti-inflammatory drugs etc).� Follow-up is ongoing to determine long term outcomes. More rigorous studies using alternative data sources robust study designs including comparison of vaccinated and unvaccinated populations as well as investigations monitoring for longer term follow up are underway; the GACVS subcommittee will continue to review this signal as more data become available. The US Food and Drug Administration (FDA) and the EMA have provided updates to the Product Information for the mRNA vaccines (Comirnaty and Spikevax). These and other agencies have issued advisories and various communication materials, to the public and healthcare professionals, with guidance or actions to take following vaccinations with mRNA vaccines. Vaccinated individuals should be instructed to seek immediate medical attention if they develop symptoms indicative of myocarditis or pericarditis such as new onset and persisting chest pain, shortness of breath, or palpitations following vaccination.Clinicians should be aware of the risk of myocarditis and pericarditis with mRNA vaccines and those most likely to be affected. They should be alert to presentations such as acute chest pain, shortness of breath and palpitations that may be suggestive of myocarditis after vaccination, especially in adolescent or young males. Coronary events are less likely to be the source of such symptoms among younger people. Where possible, suspected cases should be evaluated, provided guidance and be followed up with cardiologist consultation. �It is important to rule out other potential causes of myocarditis and pericarditis, including COVID-19 infection and other viral etiologies. An infectious disease specialist and/or rheumatologist may need to be consulted to assist in this evaluation.While acknowledging the clear benefits of the mRNA vaccines in reducing deaths and hospitalizations due to COVID-19 infections, the subcommittee encourages all health professionals to report all events of myocarditis and other adverse events observed with these and other vaccines. The WHO COVID-19 vaccine safety surveillance manual provides guidance to countries on the safety monitoring and adverse events data sharing for the new COVID-19 vaccines.The GACVS COVID-19 subcommittee will continue to review the safety data from all COVID-19 vaccines and update any advice as necessary. Open, transparent, and evidence-based communication about the potential benefits and risks to recipients and the community is essential to maintain trust. WHO is carefully monitoring the rollout of all COVID-19 vaccines and will continue to work closely with countries to manage potential risks, and to use science and data to drive response and recommendations.�Useful referencesWHO COVID-19 Vaccine Safety Surveillance Manual GACVS statement on myocarditis from 26 May 2021: https://www.who.int/news/item/26-05-2021-gacvs-myocarditis-reported-with-covid-19-mrna-vaccineshttps://brightoncollaboration.us/myocarditis-case-definition-update/Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC� Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acutemyocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics. Published online June 4, 2021. doi:10.1542/peds.2021-052478https://www.fda.gov/media/144413/download (FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS) EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19)Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices � United States, June 2021. MMWR. Early release; vol 7. Published online July 6, 2021. Surveillance of myocarditis (inflammation of the heart muscle) cases between December 2020 and May 2021. News release. Israeli Ministry of Health; June 6, 2021. Accessed July 7, 2021. Kim HW, Jenista ER,Wendell DC, et al. Patients with acute myocarditis following mRNA COVID-19 vaccination. JAMA Cardiol. Published online June 29, 2021. doi:10.1001/jamacardio.2021.2828Montgomery J, Ryan M, Engler R, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military. JAMA Cardiol. Published online June 29, 2021. doi:10.1001/jamacardio.2021.2833Centers for Disease Control and Prevention. Myocarditis and pericarditis considerations. May 28, 2021. Accessed July 7, 2021. https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis... Read more.

bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO? Gene Therapy for Transfusion - Dependent ? - thalassemia and Marketing to Resume in EU... Read more.

The most popular activities during summer include many kinds of water sports, more so now with so many spikes in heat. As we continue to enjoy this season of sun,... Read more.

Semiconductors Paving the Way to ?Vision Zero? Through Functional Safety - Electronic Design... Read more.

Royal Oak moving to put public safety millage renewal on November ballot... Read more.

El Paso Water, the NWS, Drowning Prevention Coalition of El Paso, and the city's fire department share tips on being safe during a flash flood.... Read more.

At the federal, state and local level, there are things government can do now to make sure a building collapse doesn't happen again, writes Sunrise Mayor Mike Ryan.... Read more.

Cameras are installed on buses to catch drivers passing illegally.... Read more.

Republican governor said Senate Bill 113 would have made Ohio 'one of the least restrictive states in regard to fireworks laws.'... Read more.

Board of Appeals Hearing N... Read more.

Early closures extended at Alki Beach due to illegal activity, public safety issues - KIRO Seattle... Read more.

The work follows a 2016 fatality in which a man was hit by a train on the Weymouth St crossing.... Read more.

Smoke detectors, fire extinguishers must be installed in every building in the emirate... Read more.

After the fatal collapse of a 12-story condominium in Florida last month, Richmond Mayor Levar Stoney said he is interested in working with local and state officials to examine building... Read more.

The scope of technical assistance the International Atomic Energy Agency will provide in monitoring and reviewing the planned discharge of treated water stored at the Fukushima Daiichi nuclear power plant site has been agreed. The Terms of Reference defining the objective of the IAEA's assistance, how it will be implemented and its organisational arrangements were signed yesterday by the agency and the Japanese government.... Read more.

Sportsman's Club to provide hunter education/safety program on July 24... Read more.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the implications of the DARE-19 trial results assessing dapagliflozin as a treatment for patients with type 2 diabetes hospitalized with COVID-19.... Read more.

Water Safety Class Held This Saturday For Parents And Caregivers - 9 & 10 News - 9&10 News... Read more.

A Newsy investigation finds cities rarely monitor the interior structures of towers as they age. That may soon change.... Read more.

Warburg Pincus and Tilia Holdings Announce Investment in Food Safety Net Services... Read more.

bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO? Gene Therapy for Transfusion - Dependent ? - thalassemia and Marketing to Resume in EU... Read more.